IFM Launches its second subsidiary, IFM Due, for treating inflammatory and autoimmune disease.
IFM Therapeutics Launches its second subsidiary, IFM Due, which will target the cyclic GMP-AMP Synthase, Stimulator of Interferon Genes (cGAS/STING) pathway to treat inflammatory…